Edit
Navitor Pharmaceuticals
https://www.navitorpharma.com/Last activity: 11.12.2024
Probably Closed
Navitor Pharmaceuticals, Inc., is a biopharmaceutical company developing novel medicines by targeting cellular nutrient signaling pathways. The company’s proprietary drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. Navitor’s therapeutics are designed to selectively modulate the cellular signals that are aberrant in disease processes caused by the dysregulation of mTORC1 activity to address a wide range of diseases, including metabolic, CNS, autoimmune and musculoskeletal diseases, as well as several rare disorders. The company is backed by leading financial and corporate investors, including Polaris Partners, Atlas Venture, J&J Innovation - JJDC, SR One, Brace Pharma Capital, Remeditex ventures, Sanofi Ventures and The Longevity Fund.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $56.5M
Founded date: 2010
Investors 5
| Date | Name | Website |
| - | The Longev... | longevity.... |
| - | Brace Phar... | bracepharm... |
| - | age1 | age1.com |
| - | Atlas Vent... | atlasventu... |
| - | SR One | srone.com |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 18.12.2015 | Series B | $33M | - |
| 19.06.2014 | Series A | $23.5M | - |
Mentions in press and media 14
| Date | Title | Description |
| 11.12.2024 | Eikonizo Therapeutics Receives Equity Investment From Novo Nordisk | Eikonizo Therapeutics, a Cambridge, MA-based biopharmaceutical company dedicated to developing disease-modifying therapies, received an investment from Novo Nordisk through its Science2Medicine iNNvest initiative. The amount of the deal was... |
| 18.12.2015 | Navitor grabs a $33M round as it carefully navigates toward the clinic | George Vlasuk George Vlasuk and his biotech crew at Navitor have lined up a $33 million round designed to get the first snapshot on clinical efficacy for its platform play. Brace Pharma Capital, an investment company formed by the big Brazi... |
| 18.12.2015 | Navitor Pharmaceuticals Completes $33M Series B Financing | Navitor Pharmaceuticals, Inc., a Cambridge, MA-based biopharmaceutical company developing novel medicines targeting the activation of mTORC1*, completed a $33m Series B financing. The round was led by new investor Brace Pharma Capital, LLC,... |
| 18.12.2015 | Navitor Pharmaceuticals Announces $33 Million Series B Financing | - |
| 18.12.2015 | Daily funding roundup - December 18, 2015 | Pave secured $300M; Navitor Pharmaceuticals, Inc received $33M; Checkpoint Surgical raised $7.5M Jolla Ltd., a Finnish mobile company and developer of open mobile operating system Sailfish OS, today announced that it has closed its C invest... |
| 18.12.2015 | Navitor Pharmaceuticals nabs $33M for drugs that treat aging-related disorders | “It’s the only cellular complex that, when it’s downregulated, can extend life – whether you’re looking at yeast or at mice,” Vlasuk said. The funding should be enough to push early drug candidates through proof of clinical efficacy and saf... |
| 18.12.2015 | Navitor Pharmaceuticals Nets $33M Series B | CAMBRIDGE, MA, Biopharmaceutical company developing novel medicines targeting the activation of mTORC1, today announced the completion of a $33 million Series B financing. >> Click here for more funding data on Navitor Pharmaceutic... |
| 19.06.2014 | J&J early stage collaborations span 3D printing for orthopedics, brown fat, biosensors | Brown fat as metabolic disorder treatment: Unlike normal fat cells, brown fat cells convert energy from food into heat. Brown fat has been a growing source of interest among scientists as a source of potential therapeutics for obesity and m... |
| 19.06.2014 | Navitor Pharmaceuticals Launches with $23.5 Million Series A Financing | - |
| 19.06.2014 | Navitor grabs a $23.5M A round to tackle a key crossroad for disease | A little more than a year ago, GlaxoSmithKline ($GSK) disbanded George Vlasuk's team at Sirtris and absorbed the R&D work in its Pennsylvania operations. But that didn't end the relationship. Today Vlasuk is back at the helm of a new bi... |
Show more